Eptacog beta for bleeding in Glanzmann's thrombasthenia
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This trial is testing a medication called eptacog beta (a clotting factor) to see if it helps control or prevent severe bleeding episodes in people with Glanzmann's thrombasthenia, a rare inherited bleeding disorder.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have Glanzmann's thrombasthenia (a rare bleeding disorder passed down in families).
- You must have a history of severe bleeding episodes.
- Your liver and kidneys must be working well enough.
- You cannot have a low platelet count (under 100,000).
- You must not have had a blood clot in the last 2 years.
- You cannot be taking aspirin, NSAIDs (like ibuprofen), blood thinners, or certain natural remedies while in the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at people with Glanzmann thrombasthenia, a rare bleeding disorder. It aims to gather information about the condition and how it affects people, which may help improve care and treatment in the future.
This study looks at genes and blood function in people with inherited (passed-down) problems with platelets, white blood cells, or blood clotting. It may help improve understanding of the cause of these conditions and how they work in the body.
This study uses special video imaging to try to predict when bleeding may happen in certain inherited bleeding disorders. It may help doctors better anticipate bleeding and guide safer care.
This study looks at the symptoms, severity, and outcomes of bleeding in children with Glanzmann thrombasthenia who are admitted to the hospital for active bleeding. It aims to understand the clinical pattern to improve care and treatment.
This study tests an investigational drug called Bometase Alfa to help control bleeding in people with acquired hemophilia A, a rare condition where the immune system attacks a clotting protein. If you have active bleeding from this condition, this treatment might help stop it.
This trial tests whether a medication called recombinant von Willebrand factor (vWF) can help control major bleeding in adults who are on life support with ECMO. If you are on ECMO and have a serious bleed, this treatment might help stop the bleeding.
Hear when a new Glanzmann Thrombasthenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.